Strategy: Avego BioScience Capital

Tourmaline Bio

Posted on June 5, 2023 by -

Clinical-stage company developing transformative medicines that dramatically improve the lives of patients with life-altering immune diseases.

Escient Pharmaceuticals

Posted on November 28, 2022 by -

Clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders.

Health Outlook

Posted on June 6, 2022 by -

Health prediction company utilizing proteomics and advanced statistical techniques to better predict and improve health outcomes.

Xcell Biosciences

Posted on May 23, 2022 by -

Commercial-stage life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing.

Antios Therapeutics

Posted on November 3, 2021 by -

Clinical-stage biotechnology company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV).

Caribou Biosciences

Posted on July 13, 2021 by -

Clinical-stage biotechnology company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases.

Completed IPO in 2021

Ribon Therapeutics

Posted on July 13, 2021 by -

Clinical-stage biotechnology company pursuing the development of novel small molecules that target cancer through its dependency on stress support pathways.

Arch Oncology

Posted on July 13, 2021 by -

Clinical-stage immuno-oncology company that aims to discover and develop potential best-in-class antibody therapies for the treatment of patients with cancer.

Immunocore

Posted on July 13, 2021 by -

Clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease.

Completed IPO in 2021